製品名:(4-Ethoxycarbonylphenyl)boronic acid

IUPAC Name:[4-(ethoxycarbonyl)phenyl]boronic acid

CAS番号:4334-88-7
分子式:C9H11BO4
純度:97%
カタログ番号:CM135619
分子量:193.99

包装単位 有効在庫 価格(USD) 数量
CM135619-100g in stock ƃƃƛ

研究開発用専用.

問い合わせフォーム

   refresh    

製品詳細

CAS番号:4334-88-7
分子式:C9H11BO4
融点:-
SMILESコード:C1=C(C(OCC)=O)C=CC(=C1)B(O)O
密度:
カタログ番号:CM135619
分子量:193.99
沸点:
MDL番号:MFCD02179441
保管方法:

Category Infos

Boronic Acids and Esters
Boronic acids and boronate esters are commonly used reagents in Suzuki–Miyaura coupling chemistry. Organoboron derivatives are common reagents for C–C bond formation, either through classical palladium-mediated transformations or through other newer coupling methods. Boronic esters and acids are potential intermediates in the manufacture of many active pharmaceutical ingredients (API).
Boronic Acid For Sale
Find trusted boronic acid for sale. Any requirements and problems can ask us at any time.

Column Infos

Momelotinib
GSK’s novel small molecule drug, Momelotinib (Ojjaara) has been approved by the U.S. FDA on September 15 for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythaemia vera and post-essential thrombocythaemia), in adults with anaemia.
Myelofibrosis is a rare and fatal form of bone marrow cancer, often resulting in anemia, constitutional symptoms such as fatigue, night sweats, and bone pain, and splenomegaly. These key manifestations of myelofibrosis, including anaemia, have limited treatment options and causing over 30% patients discontinuing treatment.
Momelotinib fills a significant unmet medical need, and has a potential of being a standard-of-care treatment for newly diagnosed and previously treated patients with anaemia. Under a unique mechanism of action, Momelotinib, inhibits Janus kinase (JAK) 1, JAK2, and activin A receptor, type I (ACVR1) along three key signalling pathways. The phase III study has demonstrated clinical activity against anemia, constitutional symptoms, and splenomegaly.